Pharmacological Treatments of Neuropathic Pain

Real-Life Comparisons Using Propensity Score Matching

Xavier Moisset; M. Gabrielle Pagé; Bruno Pereira; Manon Choinière

Pain. 2022;163(5):964-974.

Abstract and Introduction

Abstract

Studies comparing different drug treatments for chronic neuropathic pain (NP) are very limited. We, therefore, examined 4 recommended treatments, namely, antidepressants (duloxetine, venlafaxine, and tricyclic antidepressants), antiepileptics (gabapentine and pregabalin), weak opioids, and strong opioids, among patients with NP evaluated before first visit in a tertiary pain treatment centre and 6 months later. Patients with both a clinical diagnosis of NP and a DN4 score ≥3/7 were selected from patients enrolled in the Quebec Pain Registry. Each participant was assigned an inverse weighting of the probability of receiving any NP treatment, taking into account their age, sex, baseline pain intensity, pain duration, pain catastrophizing tendency, education level, employment, and comedications at 6-month follow-up (M6). Patients were considered as improved if they presented at least a 30% reduction on average pain intensity at M6 compared with baseline. A total of 944 patients completed both baseline and M6 evaluations. Overall, 23.0% of patients were significantly improved for pain intensity at M6. There was no significant difference in proportions patients taking or not antidepressants, gabapentinoids, or weak opioids. Among patients taking strong opioids (N = 288), 13.9% (N = 40/288) were improved vs 27.0% (177/656) of those who were not on opioids (

Table 1. Baseline characteristics of the 944 patients with chronic neuropathic pain.
Variables	Values
Age, y (mean ± SD)	53.4 ± 13.3
Female sex, % (n)	51.4 (485)
Pain duration, y (median [IQR])	3.0 [1.0–8.0]
Anglo-American ethnicity, % (n)	93.0 (878)
Presence of allodynia, % (n)	22.1 (209)
Presence of hypoesthesia, % (n)
To touch	39.8 (376)
To prick	39.6 (374)
At least one hypoesthesia	43.8 (413)
Average pain intensity in the past 7 days (mean ± SD)	6.8 ± 1.9
Brief Pain Inventory pain interference score in the past 7 days (mean ± SD)	5.9 ± 2.1
Beck depression Inventory-I, % (n)
0–9: normal range	19.9 (188)
10–18: mild to moderate depression	35.5 (335)
19–29: moderate–severe depression	30.4 (287)
30–63: severe depression	14.1 (133)
Sleep Problem Index (score 0–30) (mean ± SD)	18.3 ± 8.4
Pain Catastrophizing Scale (score 0–52) (mean ± SD)	29.8 ± 12.7
Quality of life
SF-12 Norm-Based Physical Summary Scale (mean ± SD)	28.2 ± 8.0
SF-12 Norm-Based Mental Health Summary Scale (mean ± SD)	41.0 ± 11.6
Nonpharmacological treatments, % (n)
Psychological	63.1 (596)
Physical	64.0 (604)
Education level, % (n)
Primary	8.5 (59)
Secondary	40.4 (281)
CEGEP or technical school	32.1 (223)
University	18.1 (126)
Work type, % (n)
Full-time job	19.7 (137)
Part-time job	7.3 (51)
No job	73.0 (508)

Psychological treatments correspond to relaxation, meditation, hypnosis, visualisation, distraction, psychotherapy, group therapy, self-help support group, and others. Physical treatments correspond to physiotherapy, occupational therapy, hydrotherapy, transcutaneous nerve stimulation, intramuscular stimulation, ultrasound, biofeedback, acupuncture, massage, chiropractic, ostheopathy, therapeutic touch, reflexology, Reiki, magnet therapy, exercises at home, and others.
CEGEP, French acronym for "general and professional teaching college"; IQR, interquartile range; SF-12, 12-item Short Form Survey.

Table 2. Pharmacological pain treatments used before to the first visit at the pain clinic with reason for discontinuation (possibility to note more than one reason for discontinuation) and treatment used at baseline for the 944 patients with complete evaluation both at baseline and 6-month follow-up.
	Previously used pain treatments (N = 944)	Pain treatments used at baseline (N = 944)
Antidepressants	118 (12.5)	148 (15.7)
Stopped (%) because of
Side effects	56.3
Lack of benefit	36.1
Antiepileptics	245 (26.0)	342 (36.2)
Stopped (%) because of
Side effects	58.6
Lack of benefit	39.1
At least one first-line antineuropathic drug, n (%)	294 (31.1)	400 (42.4)
Acetaminophen, n (%)	171 (18.1)	367 (38.9)
Stopped (%) because of
Side effects	32.7
Lack of benefit	53.4
NSAIDS	245 (26.0)	271 (28.7)
Stopped (%) because of
Side effects	31.9
Lack of benefit	48.0
Weak opioids	147 (15.6)	94 (10.0)
Stopped (%) because of
Side effects	44.9
Lack of benefit	43.6
Strong opioids	285 (30.2)	292 (30.9)
Stopped (%) because of
Side effects	43.3
Lack of benefit	26.4
Cannabinoids	25 (2.7)	50 (5.3)
Stopped (%) because of
Side effects	50.0
Lack of benefit	15.4
Antispastic drugs	87 (9.2)	78 (8.3)
Stopped (%) because of
Side effects	34.1
Lack of benefit	45.5
Ketamine	6 (0.6)	5 (0.5)
Topical capsaicin	2 (0.2)	2 (0.2)
Topical lidocaine	1 (0.1)	3 (0.3)

NSAIDs, nonsteroidal anti-inflammatory drugs.

Table 3. Pharmacological pain treatments used during the 6 months after the first visit (M0) at the pain clinic, either discontinued (with reason for discontinuation, possibility to note more than one reason) or used 6 months after the first visit (M6).
	Pain treatments discontinued within 6 months after initial appointment at the pain clinic (N = 944)	Pain treatments used at 6 months (N = 944)	Pain treatments initiated after initial appointment at the pain clinic (N = 944)	Ongoing pain treatments before initial appointment that was continued until at least the 6-month follow-up (N = 944)
Antineuropathic antidepressants	107 (11.3)	189 (20.0)	88 (9.3)	101 (10.7)
Stopped (%) because of
Side effects	48.7
Lack of benefit	22.6
No more needed	18.3
Antineuropathic antiepileptics	158 (16.7)	364 (38.6)	136 (14.4)	228 (24.2)
Stopped (%) because of
Side effects	46.1
Lack of benefit	19.4
No more needed	20.6
At least one first-line antineuropathic drug, n (%)	236 (25.0)	433 (45.9)	197 (20.9)	236 (25.0)
Acetaminophen, n (%)	146 (15.5)	343 (36.3)	98 (10.4)	245 (25.9)
Stopped (%) because of
Side effects	19.0
Lack of benefit	21.5
No more needed	33.9
NSAIDS	147 (15.6)	224 (23.7)	136 (14.4)	88 (9.3)
Stopped (%) because of
Side effects	15.0
Lack of benefit	22.8
No more needed	37.1
Weak opioids	115 (12.2)	94 (10.0)	46 (4.9)	48 (5.1)
Stopped (%) because of
Side effects	35.9
Lack of benefit	20.3
No more needed	23.4
Strong opioids	190 (20.1)	288 (30.5)	90 (9.5)	198 (21.0)
Stopped (%) because of
Side effects	24.6
Lack of benefit	16.4
No more needed	35.9

The third and fourth columns correspond to subgroups of patients included in the second column. Indeed, among ongoing treatments at Month 6, some were present at baseline (column 4), whereas others were initiated during the initial appointment or during the following 6 months (column 3).
NSAIDs, nonsteroidal anti-inflammatory drugs.

Table 4. Evolution of pain intensity, pain interference, sleep, catastrophizing, health-related quality of life, and depression from baseline to 6-month follow-up (M6).
	Baseline (N = 944), mean ± SD	M6 (N = 944), mean ± SD	Effect size [95% CI], Cohen d	P
Average pain intensity in the past 7 days	6.8 ± 1.9	5.9 ± 2.3	0.37 [0.31–0.43]	<0.001
	Relative average pain intensity variation between M0 and M6, % (n)
≥50% pain decrease		13.6 (128)
≥30% pain decrease		23.0 (217)
≥10% pain decrease		50.9 (480)
Stable pain (variation < 10%)		23.9 (226)
≥10% pain increase		25.2 (238)
≥30% pain increase		9.5 (90)
≥50% pain increase		5.0 (47)
Brief Pain Inventory interference score in the past 7 days (global score)	5.9 ± 2.1	5.0 ± 2.5	0.42 [0.36–0.49]	<0.001
	Relative pain interference variation between M0 and M6, % (n)
≥50% pain decrease		16.2 (153)
≥30% pain decrease		30.6 (289)
≥10% pain decrease		51.3 (484)
Stable pain (variation <10%)		27.3 (258)
≥10% pain increase		21.4 (202)
≥30% pain increase		10.7 (101)
≥50% pain increase		6.6 (62)
Sleep problem index (score 0–30)	18.3 ± 8.4	15.5 ± 9.2	0.37 [0.30–0.43]	<0.001
Quality of life
SF-12 Physical Summary Scale	28.2 ± 8.0	30.3 ± 9.1	0.28 [0.22–0.35]	<0.001
SF-12 Mental Health Summary Scale	41.0 ± 11.6	41.9 ± 11.8	0.08 [0.02–0.15]	0.010
	% (n)	% (n)	Cramér's V
Beck Depression Inventory, % (n)			0.09 [0.05–0.12]	<0.001
0–9: normal range	19.9 (188)	25.6 (241)
10–18: mild-to-moderate depression	35.5 (335)	34.5 (325)
19–29: moderate-to-severe depression	30.4 (287)	26.5 (249)
30–63: severe depression	14.1 (133)	13.4 (126)

CI, confidence interval; SF-12, 12-item Short Form Survey.

Table 5. Mean pain intensity variation from baseline to 6-month follow-up depending on the type of medications taken at baseline.
Treatment (number of patients taking the medication, of 944)	Taken at baseline, median [IQR]	Not taken at baseline, median [IQR]	Difference, median [IQR]	P
Weak opioids (n = 94 vs 850)	−1 [−3 to 0]	−1 [−2 to 1]	0 [−0.54 to 0.51]	0.111
Strong opioids (n = 292 vs 652)	0 [−2 to 1]	−1 [−2 to 0]	1 [0.65 to 1.35]	0.451
Antiepileptics (n = 342 vs 602)	−1 [−2 to 1]	0 [−2 to 1]	−1 [−1.33 to 0.66]	0.396
Antidepressants (n = 148 vs 796)	0 [−2 to 1]	−1 [−2 to 0]	1 [−0.56 to 1.44]	0.270

A negative value for pain variation is in favor of a pain decrease between baseline and M6.
IQR, interquartile range.

Table 6. Mean pain intensity variation from baseline to 6-month follow-up (M6) depending on the type of medications taken at M6.
Treatment (number of patients taking the medication, of 944)	Taken at M6, median [IQR]	Not taken at M6, median [IQR]	Difference, median [IQR]	P
Weak opioids (n = 94 vs 850)	0 [−2 to 0]	−1 [−2 to 1]	1 [−0.46 to 1.53]	0.853
Strong opioids (n = 288 vs 656)	0 [−1 to 1]	−1 [−2 to 0]	1 [0.65 to 1.35]	0.012
Antiepileptics (n = 364 vs 580)	−1 [−2 to 0]	0 [−2 to 1]	−1 [−1.33 to 0.67]	0.351
Antidepressants (n = 189 vs 755)	0 [−2 to 0]	−1 [−2 to 1]	1 [−0.60 to 1.40]	0.716

A negative value for pain variation is in favour of a pain decrease between baseline and M6. IQR, interquartile range.

Table 7. Characteristics of patients receiving strong opioids at 6-month follow-up or not, before application of the propensity score and after application of the inverse probability of the treatment weighting method.
	Before propensity score			After inverse probability of treatment weighting
	Opioids (n = 288)	No opioids (n = 656)	P	Opioids (n = 288)	No opioids (n = 656)	·d·	P
Age, y (mean ± SD)	52.7 ± 12.5	53.7 ± 13.6	0.28	53.2 ± 12.8	53.2 ± 13.7	0.002	0.99
Female sex	137 (47.6%)	348 (53.1%)	0.12	51.3%	51.2%	0.002	0.98
Pain duration, y (median [IQR])	4.0 [1.5–9.5]	3.0 [1.0–7.0]	<0.001	3.0 [1.3–8.0]	3.0 [1.3–8.0]	0.021	0.79
Average pain intensity in the past 7 days at baseline (mean ± SD)	7.1 ± 1.8	6.6 ± 2.0	<0.001	6.8 ± 1.8	6.8 ± 1.9	0.021	0.79
Percentage (%) of patients with at least 30% pain intensity decrease	13.9	27.0	<0.001	14.2	26.0	0.298	<0.001
Brief Pain Inventory pain interference score in the past 7 days (mean ± SD)	6.4 ± 2.0	5.7 ± 2.1	<0.001	6.0 ± 2.1	5.9 ± 2.1	0.051	0.58
Percentage (%) of patients with at least 30% pain interference decrease	23.3	33.9	<0.001	22.5	32.6	0.228	0.003
Antiepileptics (yes, n (%))	159 (55.2%)	205 (31.3%)	<0.001	36.1	38.8	0.056	0.48
Antidepressants (yes, n (%))	94 (32.6%)	95 (14.5%)	<0.001	20.4	19.5	0.021	0.78
Weak opioids (yes, n (%))	16 (5.6%)	78 (11.9%)	0.003	13.5	10.0	0.108	0.34
Nonpharmacological treatments (%)
Psychological							0.04
Never used	28.5	40.6	<0.001	34.3	38.3	Ref
Past use	67.7	54.0		62.8	54.8	0.120
Current use	3.8	5.5		2.9	6.9	0.230
Physical							0.82
Never used	34.7	36.7	0.78	34.8	36.4	Ref
Past use	56.9	56.1		58.5	56.2	0.042
Current use	8.3	7.3		6.6	7.4	0.024
PCS (mean ± SD)	31.9 ± 12.8	28.9 ± 12.6	<0.001	29.8 ± 12.5	29.0 ± 13.4	0.063	0.51
Education (%)			0.004				0.92
Primary	9.8	7.4		7.6	8.2	Ref
Secondary	42.5	34.5		35.3	37.4	0.008
CEGEP or technical school	29.6	28.8		30.8	28.7	0.060
University	18.1	28.8		26.2	25.7	0.041
Work (yes, n (%))			<0.001				0.75
Full-time job	13.5	23.5		21.4	20.4	Ref
Part-time job	4.5	8.7		6.3	8.2	0.078
Others	81.9	67.8		72.3	71.4	0.014
SF-12 Mental (mean ± SD)	39.3 ± 11.3	41.8 ± 11.6	0.003	41.8 ± 11.5	41.1 ± 11.6	0.061	0.47

Antineuropathic antiepileptics, antidepressants, and weak opioids correspond to treatments received at M6.
CEGEP, French acronym for "general and professional teaching college"; ·d·, standardized difference (difference is not significant when ·d·< 0.20); IQR, interquartile range; PCS, Pain Catastrophizing Scale; PCS, Pain Catastrophizing Scale; SF-12, 12-item Short Form Survey.

processing....

Pharmacological Treatments of Neuropathic Pain

Real-Life Comparisons Using Propensity Score Matching

Abstract and Introduction

Abstract

Tables

Tables

Tables

Tables

Tables

Tables

Tables

References

Authors and Disclosures

Authors and Disclosures

Sidebar

Appendix A. Supplemental Digital Content

Most Popular Articles

Email This

Feedback